David Dible's Linkedin Analytics

“The art of storytelling is incredibly important. Learning to tell a story is critically important because that’s how the money works. The money flows as a function of the story.” Don Valentine, Sequoia Capital I am an experienced, scientifically curious, strategic advisor that has been using neurodiverse thinking to generate high value "bespoke" equity stories that have been critical to the success of multiple pharma/biotech and healthcare companies globally. These stories ideally position my clients' expertise, assets, and value creation potential with the key audiences that are critical for their success, namely investors, partners and talent. I bring informed, street-wise thinking and a deep understanding of finance and investment, based on my background as top rated analyst and successful investor. My overall lived experience and outsider mindset has allowed me to successfully "Advise Biotech CEOs differently." I have crafted appealing stories and led the strategic communications planning and execution for many of the industry's most successful pharma/biotech and medtech companies. I have played a key role in more 35 IPOs across Europe and the US and numerous secondary and private financing rounds. I have also developed the investor pitches to support multiple major M&A transactions. I have also advised on the communication of complex scientific and clinical development news. Amongst the clients I have supported during critical times in their companies development are: Actelion, Lonza, Algeta, argenx, Zeneca, BONESUPPORT, HutchMed, Zentiva, immatics,, Movetis, Abingworth, Abivax, Enterome, Glaxo, Arjo, Wellcome, Sosei Heptares,, Biacore, NicOx, Quell Therapeutics, Cambridge Antibody Technology, Karolinska Development, Protek, and Transgene and Vectura. Selected significant projects include: • Actelion (successful defence against activist shareholder Elliott Advisors) • Lonza (M&A/financial communications) including the $5.5 billion acquisition of Capsugel, • Zeneca (lead analyst on the demerger from ICI and the accompanying £1.3 billion funding) • argenx- IPO on Euronext Brussels • Zentiva (IPO, M&A) including its bid defence in relation to its acquisition by Sanofi • Alere - successful acquisition of Axis-Shield • Vectura - merger with Skyepharma • Cambridge Antibody Technology, last fund raising prior to its acquisition by AstraZeneca • Algeta, from its time as an emerging private company though to its $2.9 billion acquisition by Bayer